$20.22
+0.3
(+1.51%)▲
2.42%
Downside
Day's Volatility :4.92%
Upside
2.55%
24.43%
Downside
52 Weeks Volatility :75.96%
Upside
68.19%
Period | 10x Genomics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -27.8% | 6.5% | 0.0% |
6 Months | -53.91% | 7.1% | 0.0% |
1 Year | -67.2% | 9.8% | 0.0% |
3 Years | -88.91% | 14.2% | -20.2% |
Market Capitalization | 2.3B |
Book Value | $6.01 |
Earnings Per Share (EPS) | -2.24 |
Wall Street Target Price | 29.57 |
Profit Margin | -42.26% |
Operating Margin TTM | -42.12% |
Return On Assets TTM | -13.06% |
Return On Equity TTM | -34.75% |
Revenue TTM | 625.4M |
Revenue Per Share TTM | 5.3 |
Quarterly Revenue Growth YOY | 5.0% |
Gross Profit TTM | 396.0M |
EBITDA | -164.1M |
Diluted Eps TTM | -2.24 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.59 |
EPS Estimate Next Year | -1.07 |
EPS Estimate Current Quarter | -0.5 |
EPS Estimate Next Quarter | -0.48 |
What analysts predicted
Upside of 46.24%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 146.3M | ↑ 105.83% |
Net Income | -112.5M | ↑ 499.54% |
Net Profit Margin | -76.88% | ↓ 50.49% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 245.9M | ↑ 68.06% |
Net Income | -31.3M | ↓ 72.22% |
Net Profit Margin | -12.71% | ↑ 64.17% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 298.8M | ↑ 21.53% |
Net Income | -542.7M | ↑ 1636.68% |
Net Profit Margin | -181.61% | ↓ 168.9% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 490.5M | ↑ 64.13% |
Net Income | -58.2M | ↓ 89.27% |
Net Profit Margin | -11.87% | ↑ 169.74% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 516.4M | ↑ 5.28% |
Net Income | -166.0M | ↑ 185.11% |
Net Profit Margin | -32.15% | ↓ 20.28% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 618.7M | ↑ 19.81% |
Net Income | -255.1M | ↑ 53.67% |
Net Profit Margin | -41.23% | ↓ 9.08% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 156.2M | ↑ 19.2% |
Net Income | -17.2M | ↓ 58.93% |
Net Profit Margin | -11.02% | ↑ 20.96% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 134.3M | ↓ 14.05% |
Net Income | -50.7M | ↑ 194.78% |
Net Profit Margin | -37.79% | ↓ 26.77% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 146.8M | ↑ 9.33% |
Net Income | -62.4M | ↑ 22.99% |
Net Profit Margin | -42.51% | ↓ 4.72% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 153.6M | ↑ 4.65% |
Net Income | -93.0M | ↑ 48.98% |
Net Profit Margin | -60.52% | ↓ 18.01% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 184.0M | ↑ 19.74% |
Net Income | -49.0M | ↓ 47.36% |
Net Profit Margin | -26.61% | ↑ 33.91% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 141.0M | ↓ 23.36% |
Net Income | -59.9M | ↑ 22.46% |
Net Profit Margin | -42.52% | ↓ 15.91% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 124.3M | ↑ 64.41% |
Total Liabilities | 344.3M | ↑ 83.02% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 605.9M | ↑ 387.43% |
Total Liabilities | 185.8M | ↓ 46.02% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 929.3M | ↑ 53.38% |
Total Liabilities | 190.3M | ↑ 2.38% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.0B | ↑ 9.63% |
Total Liabilities | 201.3M | ↑ 5.78% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.0B | ↑ 1.0% |
Total Liabilities | 223.2M | ↑ 10.92% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 965.1M | ↓ 6.2% |
Total Liabilities | 224.1M | ↑ 0.39% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.0B | ↑ 3.29% |
Total Liabilities | 223.2M | ↑ 1.28% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.0B | ↓ 1.45% |
Total Liabilities | 211.6M | ↓ 5.19% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 989.6M | ↓ 2.41% |
Total Liabilities | 196.3M | ↓ 7.23% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 948.5M | ↓ 4.15% |
Total Liabilities | 203.3M | ↑ 3.56% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 965.1M | ↑ 1.75% |
Total Liabilities | 224.1M | ↑ 10.22% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 922.9M | ↓ 4.38% |
Total Liabilities | 204.1M | ↓ 8.93% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -76.4M | ↑ 614.17% |
Investing Cash Flow | -6.7M | ↑ 78.62% |
Financing Cash Flow | 105.4M | ↑ 411.91% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 34.6M | ↓ 145.32% |
Investing Cash Flow | -42.8M | ↑ 537.46% |
Financing Cash Flow | 414.6M | ↑ 293.47% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -217.9M | ↓ 729.27% |
Investing Cash Flow | -38.4M | ↓ 10.23% |
Financing Cash Flow | 468.9M | ↑ 13.1% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -21.4M | ↓ 90.19% |
Investing Cash Flow | -106.7M | ↑ 177.98% |
Financing Cash Flow | 35.3M | ↓ 92.47% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -33.6M | ↑ 57.24% |
Investing Cash Flow | -350.9M | ↑ 228.76% |
Financing Cash Flow | 15.8M | ↓ 55.19% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 13.7M | ↓ 243.49% |
Investing Cash Flow | -33.2M | ↑ 1.66% |
Financing Cash Flow | 5.0M | ↑ 145.27% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.1M | ↓ 130.06% |
Investing Cash Flow | 120.0M | ↓ 461.62% |
Financing Cash Flow | -3.4M | ↓ 168.27% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -11.5M | ↑ 179.42% |
Investing Cash Flow | -4.5M | ↓ 103.72% |
Financing Cash Flow | 7.1M | ↓ 307.85% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -25.3M | ↑ 119.54% |
Investing Cash Flow | 4.9M | ↓ 209.82% |
Financing Cash Flow | 4.4M | ↓ 38.36% |
Sell
Neutral
Buy
10x Genomics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() 10x Genomics Inc | 2.15% | -53.91% | -67.2% | -88.91% | -62.24% |
![]() Solventum Corp | 13.4% | -16.71% | -16.71% | -16.71% | -16.71% |
![]() Veeva Systems Inc. | 1.24% | -10.63% | -7.18% | -43.19% | 9.43% |
![]() Ge Healthcare Technologies Inc. | 2.46% | 9.25% | 3.22% | 32.12% | 32.12% |
![]() Healthequity Inc | -3.68% | 3.76% | 26.99% | 6.89% | -2.18% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() 10x Genomics Inc | NA | NA | NA | -1.59 | -0.35 | -0.13 | NA | 6.01 |
![]() Solventum Corp | NA | NA | NA | 6.26 | 0.17 | 0.08 | NA | NA |
![]() Veeva Systems Inc. | 54.35 | 54.35 | 1.35 | 4.76 | 0.13 | 0.06 | NA | 30.25 |
![]() Ge Healthcare Technologies Inc. | 23.5 | 23.5 | 20.11 | 4.27 | 0.22 | 0.06 | 0.0 | 16.23 |
![]() Healthequity Inc | 85.91 | 85.91 | 2.29 | 2.19 | 0.04 | 0.03 | NA | 24.11 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() 10x Genomics Inc | Buy | $2.3B | -62.24% | NA | -42.26% |
![]() Solventum Corp | Hold | $10.8B | -16.71% | NA | 15.73% |
![]() Veeva Systems Inc. | Buy | $29.8B | 9.43% | 54.35 | 22.34% |
![]() Ge Healthcare Technologies Inc. | Buy | $36.9B | 32.12% | 23.5 | 8.05% |
![]() Healthequity Inc | Buy | $6.9B | -2.18% | 85.91 | 7.71% |
Insights on 10x Genomics Inc
Revenue is down for the last 2 quarters, 183.97M → 141.00M (in $), with an average decrease of 23.4% per quarter
Netprofit is down for the last 2 quarters, -48.95M → -59.94M (in $), with an average decrease of 22.5% per quarter
In the last 1 year, Healthequity Inc has given 27.0% return, outperforming this stock by 94.2%
In the last 3 years, Healthequity Inc has given 6.9% return, outperforming this stock by 95.8%
FMR Inc
Vanguard Group Inc
Baillie Gifford & Co Limited.
ARK Investment Management LLC
BlackRock Inc
Morgan Stanley - Brokerage Accounts
10x Genomics Inc’s price-to-earnings ratio stands at None
Read Moreadvancing human health requires a greater understanding of biology, and that understanding starts with the cell. we enable researchers to drive exponential progress in oncology, immunology, neuroscience, and more with novel single cell, spatial, and in situ tools that have been cited in over 3,000 publications and continually improved by our dedicated scientific team. our aim: to develop innovative instruments, reagents, and software that allow you to see your biological system at a resolution that matches its complexity.
Organization | 10x Genomics Inc |
Employees | 1259 |
CEO | Dr. Serge Saxonov Ph.D. |
Industry | Commercial Services |